Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
ID: 357165Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357165

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-072.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)," aimed at accelerating the development of evidence-based cancer interventions that address health disparities among diverse populations in the United States. This initiative will support research that tests the impact of cancer-related interventions on outcomes through a pragmatic trial design, structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding amounts capped at $500,000 for the UG3 phase and $750,000 for the UH3 phase. Interested parties should note that applications are due by November 17, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-072-Full-Announcement.html
    PAR-25-072.html
    The National Cancer Institute (NCI) under the Department of Health and Human Services has issued a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)." This initiative is designed to accelerate the development of evidence-based cancer interventions, focusing on diverse populations and settings across the United States. The funding will support research testing the impact of cancer-related interventions on outcomes through a pragmatic trial design. The program is structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include higher education institutions, nonprofits, and government entities, with awards capped at $500,000 for UG3 and $750,000 for UH3 phases. Applications must address health disparities and demonstrate collaboration with key stakeholders. This funding opportunity underscores the government's commitment to enhancing cancer care through rigorous testing in real-world contexts, ultimately aiming to improve public health outcomes for underserved populations.
    Similar Opportunities
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant to enhance cancer screening and preventive services for populations experiencing health disparities. This initiative aims to address barriers to cancer care by developing interventions that operate at multiple levels, including patient, clinician, healthcare settings, and community factors, while encouraging collaboration with community partners. The funding reflects NIH's commitment to advancing health equity, particularly for historically underserved groups, and requires applicants to submit a Plan for Enhancing Diverse Perspectives. Interested applicants can find more information and guidelines at the provided link, with applications due by January 7, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)" aimed at investigating the biological and genetic mechanisms underlying cancer health disparities among diverse racial and ethnic populations. This funding initiative encourages innovative pilot studies that focus on identifying cancer risk factors, developing preventative strategies, and enhancing research methodologies, while fostering a multidisciplinary cohort dedicated to cancer health disparities research. Eligible applicants include a wide range of entities such as educational institutions, nonprofits, and tribal organizations, with a maximum funding amount of $275,000 available for a two-year project period. Interested parties should note that the application deadline is November 16, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-244.html for further details.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.
    Notice of Intent to Publish a Funding Opportunity Announcement for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) initiative, specifically targeting Tobacco Use Treatment for Cancer Survivors. This initiative aims to fund up to three research projects that will develop and test strategies to enhance the delivery and sustainability of tobacco use treatment services for cancer survivors, utilizing the UG3/UH3 Exploratory/Developmental Cooperative Agreement activity code, which requires clinical trials. The total estimated funding for this opportunity is $2.4 million, with applications expected to be due in late Fall 2024 and awards anticipated by July 1, 2025. Interested applicants are encouraged to prepare by reviewing related materials and attending a pre-application webinar, details of which will be announced following the NOFO publication.